| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/DOM.13133 |
| P698 | PubMed publication ID | 29053202 |
| P50 | author | Julio Rosenstock | Q60996888 |
| P2093 | author name string | John Yee | |
| John F McCarthy | |||
| Robert Henry | |||
| Michelle Baron | |||
| Tom Alessi | |||
| Ginger Carls | |||
| P2860 | cites work | Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors | Q26741537 |
| Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q28254549 | ||
| Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes | Q33573537 | ||
| Barriers to insulin initiation: the translating research into action for diabetes insulin starts project | Q33751437 | ||
| Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide | Q33835762 | ||
| Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. | Q33835897 | ||
| Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study | Q34114735 | ||
| Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors | Q34133889 | ||
| Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus | Q34737169 | ||
| Patient perceptions of diabetes and diabetes therapy: assessing quality of life | Q34906433 | ||
| Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment | Q35001542 | ||
| Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study | Q35558388 | ||
| Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. | Q36426795 | ||
| A systematic review of patient-reported measures of burden of treatment in three chronic diseases | Q36975806 | ||
| Diabetes Medication Satisfaction Tool: a focus on treatment regimens | Q37022869 | ||
| Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes | Q37106564 | ||
| Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily | Q37420158 | ||
| Adherence to therapies in patients with type 2 diabetes. | Q37468440 | ||
| A review of diabetes treatment adherence and the association with clinical and economic outcomes | Q37852413 | ||
| The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review | Q37916689 | ||
| Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus | Q37993945 | ||
| Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1RA and DPP4 Therapies in Patients With Type 2 Diabetes | Q38628189 | ||
| Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. | Q38628195 | ||
| Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes | Q42165729 | ||
| Treatment satisfaction of diabetic patients: what are the contributing factors? | Q42613775 | ||
| Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial | Q42654585 | ||
| Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin | Q43797077 | ||
| Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes | Q44460021 | ||
| Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States | Q45099109 | ||
| Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. | Q45829732 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes | Q47333592 | ||
| Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus | Q47333601 | ||
| Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. | Q48071098 | ||
| Associations between complications and health-related quality of life in individuals with diabetes. | Q48419120 | ||
| Achievement of goals in U.S. diabetes care, 1999-2010. | Q51045064 | ||
| DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. | Q51379684 | ||
| The impact of type 2 diabetes mellitus on daily functioning. | Q53547827 | ||
| P921 | main subject | metformin | Q19484 |
| P577 | publication date | 2017-10-20 | |
| P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
| P1476 | title | Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin |
Search more.